FDA adds warning label to RSV vaccines Abrysvo and Arexvy about the risk for Guillain-Barré syndrome
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...
pulmonologyadvisor17h
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Mena FN3d
Abrysvo Or Arexvy Global Market Report 2025: Market Size, Growth Trends, Key Players, And Future Market Forecasts
LONDON, GREATER LONDON, UNITED KINGDOM, January 22, 2025 /EINPresswire / -- What has been the historic growth trend in the abrysvo or arexvy global market and what is expected in the coming years?
Medscape2d
RSV Vaccines Will Carry Warning for Guillain-Barré Syndrome
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
pulmonologyadvisor3d
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome Warning
The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...
cidrap.umn13h
Real-world study: RSV vaccine 78% to 80% effective against infection, severe illness in older US veterans
The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...
healthday on MSN11d
FDA Adds Warning Label to RSV Vaccines Abrysvo and Arexvy
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing informa ...
FDA Urges Guillain-Barré Syndrome Warning On Labels Of RSV Vaccines Abrysvo And Arexvy
The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...
Pharm Exec16d
FDA Mandates Updates to Prescribing Information for RSV Vaccines Abrysvo, Arexvy for Increased Guillain-Barré Syndrome Risk
Abrysvo and Arexvy will now be required to come with labeling that includes a warning about a potential increased risk of Guillain-Barré Syndrome. The FDA announced that it has mandated updates to the ...